

# Yangbing Zhao

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/8636884/yangbing-zhao-publications-by-year.pdf>

**Version:** 2024-04-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

52 papers	7,321 citations	36 h-index	54 g-index
54 ext. papers	8,741 ext. citations	9.1 avg, IF	5.71 L-index

#	Paper	IF	Citations
52	CCR5-edited CD4+ T cells augment HIV-specific immunity to enable post-rebound control of HIV replication. <i>Journal of Clinical Investigation</i> , <b>2021</b> , 131,	15.9	15
51	CRISPR-engineered T cells in patients with refractory cancer. <i>Science</i> , <b>2020</b> , 367,	33.3	448
50	iGUIDE: an improved pipeline for analyzing CRISPR cleavage specificity. <i>Genome Biology</i> , <b>2019</b> , 20, 14	18.3	20
49	First-in-Human Assessment of Feasibility and Safety of Multiplexed Genetic Engineering of Autologous T Cells Expressing NY-ESO -1 TCR and CRISPR/Cas9 Gene Edited to Eliminate Endogenous TCR and PD-1 (NYCE T cells) in Advanced Multiple Myeloma (MM) and Sarcoma. <i>Blood</i> , <b>2019</b> , 134, 49-49	2.2	7
48	CRISPR/Cas9 genome editing: Fueling the revolution in cancer immunotherapy. <i>Current Research in Translational Medicine</i> , <b>2018</b> , 66, 39-42	3.7	31
47	Dominant-Negative TGF- $\beta$ Receptor Enhances PSMA-Targeted Human CAR T Cell Proliferation And Augments Prostate Cancer Eradication. <i>Molecular Therapy</i> , <b>2018</b> , 26, 1855-1866	11.7	247
46	Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells. <i>Nature</i> , <b>2018</b> , 558, 307-312	32.4	362
45	Advancing chimeric antigen receptor T cell therapy with CRISPR/Cas9. <i>Protein and Cell</i> , <b>2017</b> , 8, 634-643	7.2	64
44	Increasing the safety and efficacy of chimeric antigen receptor T cell therapy. <i>Protein and Cell</i> , <b>2017</b> , 8, 573-589	7.2	47
43	Novel T cells with improved in vivo anti-tumor activity generated by RNA electroporation. <i>Protein and Cell</i> , <b>2017</b> , 8, 514-526	7.2	10
42	Augmentation of Antitumor Immunity by Human and Mouse CAR T Cells Secreting IL-18. <i>Cell Reports</i> , <b>2017</b> , 20, 3025-3033	10.6	205
41	A versatile system for rapid multiplex genome-edited CAR T cell generation. <i>Oncotarget</i> , <b>2017</b> , 8, 17002-17011	3.3	237
40	Safety and Efficacy of Intratumoral Injections of Chimeric Antigen Receptor (CAR) T Cells in Metastatic Breast Cancer. <i>Cancer Immunology Research</i> , <b>2017</b> , 5, 1152-1161	12.5	181
39	Multiplex Genome Editing to Generate Universal CAR T Cells Resistant to PD1 Inhibition. <i>Clinical Cancer Research</i> , <b>2017</b> , 23, 2255-2266	12.9	495
38	Blockade of Programmed Death 1 Augments the Ability of Human T Cells Engineered to Target NY-ESO-1 to Control Tumor Growth after Adoptive Transfer. <i>Clinical Cancer Research</i> , <b>2016</b> , 22, 436-47	12.9	84
37	A Chimeric Switch-Receptor Targeting PD1 Augments the Efficacy of Second-Generation CAR T Cells in Advanced Solid Tumors. <i>Cancer Research</i> , <b>2016</b> , 76, 1578-90	10.1	308
36	Affinity-Tuned ErbB2 or EGFR Chimeric Antigen Receptor T Cells Exhibit an Increased Therapeutic Index against Tumors in Mice. <i>Cancer Research</i> , <b>2015</b> , 75, 3596-607	10.1	298

35	Identification of chimeric antigen receptors that mediate constitutive or inducible proliferation of T cells. <i>Cancer Immunology Research</i> , <b>2015</b> , 3, 356-67	12.5	181
34	Multiplex Cripsr/Cas9 Genome Editing to Generate Potent Universal CART and PD1-Deficient Cells Against Leukemia. <i>Blood</i> , <b>2015</b> , 126, 4280-4280	2.2	12
33	Improved Anti-Leukemia Activities of Adoptively Transferred T Cells Expressing Bites. <i>Blood</i> , <b>2015</b> , 126, 4431-4431	2.2	2
32	Rigorous optimization and validation of potent RNA CAR T cell therapy for the treatment of common epithelial cancers expressing folate receptor. <i>Oncotarget</i> , <b>2015</b> , 6, 28911-28	3.3	35
31	Relation of clinical culture method to T-cell memory status and efficacy in xenograft models of adoptive immunotherapy. <i>Cytotherapy</i> , <b>2014</b> , 16, 619-30	4.8	74
30	Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies. <i>Cancer Immunology Research</i> , <b>2014</b> , 2, 112-20	12.5	558
29	Nature of tumor control by permanently and transiently modified GD2 chimeric antigen receptor T cells in xenograft models of neuroblastoma. <i>Cancer Immunology Research</i> , <b>2014</b> , 2, 1059-70	12.5	52
28	Engineered T cells for cancer therapy. <i>Cancer Immunology, Immunotherapy</i> , <b>2014</b> , 63, 969-75	7.4	90
27	Adoptive immunotherapy for cancer or viruses. <i>Annual Review of Immunology</i> , <b>2014</b> , 32, 189-225	34.7	201
26	Regimen-specific effects of RNA-modified chimeric antigen receptor T cells in mice with advanced leukemia. <i>Human Gene Therapy</i> , <b>2013</b> , 24, 717-27	4.8	84
25	T cells expressing chimeric antigen receptors can cause anaphylaxis in humans. <i>Cancer Immunology Research</i> , <b>2013</b> , 1, 26-31	12.5	376
24	Enhanced function of redirected human T cells expressing linker for activation of T cells that is resistant to ubiquitylation. <i>Human Gene Therapy</i> , <b>2013</b> , 24, 27-37	4.8	15
23	Distinct Signaling By Chimeric Antigen Receptors (CARs) Containing CD28 Signaling Domain Versus 4-1BB In Primary Human T Cells. <i>Blood</i> , <b>2013</b> , 122, 2902-2902	2.2	2
22	T cells expressing chimeric antigen receptors can cause anaphylaxis in humans. <i>Cancer Immunology Research</i> , <b>2013</b> , 1, 26-31	12.5	94
21	TCR affinity and specificity requirements for human regulatory T-cell function. <i>Blood</i> , <b>2012</b> , 119, 3420-30	2.2	37
20	Mutant presenilin-1 deregulated peripheral immunity exacerbates Alzheimer-like pathology. <i>Journal of Cellular and Molecular Medicine</i> , <b>2011</b> , 15, 327-38	5.6	10
19	Development of a genetically-modified novel T-cell receptor for adoptive cell transfer against renal cell carcinoma. <i>Journal of Immunological Methods</i> , <b>2011</b> , 366, 43-51	2.5	14
18	Treatment of advanced leukemia in mice with mRNA engineered T cells. <i>Human Gene Therapy</i> , <b>2011</b> , 22, 1575-86	4.8	149

17	Multiple injections of electroporated autologous T cells expressing a chimeric antigen receptor mediate regression of human disseminated tumor. <i>Cancer Research</i> , <b>2010</b> , 70, 9053-61	10.1	334
16	A high molecular weight melanoma-associated antigen-specific chimeric antigen receptor redirects lymphocytes to target human melanomas. <i>Cancer Research</i> , <b>2010</b> , 70, 3027-33	10.1	58
15	Gene therapy using genetically modified lymphocytes targeting VEGFR-2 inhibits the growth of vascularized syngenic tumors in mice. <i>Journal of Clinical Investigation</i> , <b>2010</b> , 120, 3953-68	15.9	163
14	Lentiviral vector design for optimal T cell receptor gene expression in the transduction of peripheral blood lymphocytes and tumor-infiltrating lymphocytes. <i>Human Gene Therapy</i> , <b>2009</b> , 20, 630-40	4.8	57
13	A herceptin-based chimeric antigen receptor with modified signaling domains leads to enhanced survival of transduced T lymphocytes and antitumor activity. <i>Journal of Immunology</i> , <b>2009</b> , 183, 5563-74	5.3	227
12	Recognition of NY-ESO-1+ tumor cells by engineered lymphocytes is enhanced by improved vector design and epigenetic modulation of tumor antigen expression. <i>Cancer Immunology, Immunotherapy</i> , <b>2009</b> , 58, 383-94	7.4	70
11	Single and dual amino acid substitutions in TCR CDRs can enhance antigen-specific T cell functions. <i>Journal of Immunology</i> , <b>2008</b> , 180, 6116-31	5.3	248
10	Construction and Pre-Clinical Evaluation of An Anti-CD19 Chimeric Antigen Receptor. <i>Blood</i> , <b>2008</b> , 112, 4623-4623	2.2	1
9	High-affinity TCRs generated by phage display provide CD4+ T cells with the ability to recognize and kill tumor cell lines. <i>Journal of Immunology</i> , <b>2007</b> , 179, 5845-54	5.3	162
8	Extrathymic generation of tumor-specific T cells from genetically engineered human hematopoietic stem cells via Notch signaling. <i>Cancer Research</i> , <b>2007</b> , 67, 2425-9	10.1	78
7	Enhanced antitumor activity of murine-human hybrid T-cell receptor (TCR) in human lymphocytes is associated with improved pairing and TCR/CD3 stability. <i>Cancer Research</i> , <b>2006</b> , 66, 8878-86	10.1	325
6	High-efficiency transfection of primary human and mouse T lymphocytes using RNA electroporation. <i>Molecular Therapy</i> , <b>2006</b> , 13, 151-9	11.7	229
5	Transduction of an HLA-DP4-restricted NY-ESO-1-specific TCR into primary human CD4+ lymphocytes. <i>Journal of Immunotherapy</i> , <b>2006</b> , 29, 398-406	5	23
4	Primary human lymphocytes transduced with NY-ESO-1 antigen-specific TCR genes recognize and kill diverse human tumor cell lines. <i>Journal of Immunology</i> , <b>2005</b> , 174, 4415-23	5.3	158
3	Recognition of fresh human tumor by human peripheral blood lymphocytes transduced with a bicistronic retroviral vector encoding a murine anti-p53 TCR. <i>Journal of Immunology</i> , <b>2005</b> , 175, 5799-808	5.3	111
2	Inhibition of invariant chain expression in dendritic cells presenting endogenous antigens stimulates CD4+ T-cell responses and tumor immunity. <i>Blood</i> , <b>2003</b> , 102, 4137-42	2.2	28
1	Donor-type chimerism determination by competitive polymerase chain reaction (PCR) in a primate model for bone marrow transplantation. <i>Transplantation</i> , <b>1999</b> , 68, 1573-7	1.8	4